74 related articles for article (PubMed ID: 20621639)
1. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays.
Munić V; Kelnerić Z; Mikac L; Eraković Haber V
Eur J Pharm Sci; 2010 Sep; 41(1):86-95. PubMed ID: 20621639
[TBL] [Abstract][Full Text] [Related]
2. First characterization of fish P-glycoprotein (abcb1) substrate specificity using determinations of its ATPase activity and calcein-AM assay with PLHC-1/dox cell line.
Zaja R; Lončar J; Popovic M; Smital T
Aquat Toxicol; 2011 May; 103(1-2):53-62. PubMed ID: 21392495
[TBL] [Abstract][Full Text] [Related]
3. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
4. Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.
Pérez-Simón JA; Valverde B; Martínez A; Tabernero D; Almeida J; Gutierrez N; San Miguel JF; Orfao A
Cytometry; 1999 Feb; 38(1):24-9. PubMed ID: 10088973
[TBL] [Abstract][Full Text] [Related]
5. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers.
Endter S; Becker U; Daum N; Huwer H; Lehr CM; Gumbleton M; Ehrhardt C
Cell Tissue Res; 2007 Apr; 328(1):77-84. PubMed ID: 17165089
[TBL] [Abstract][Full Text] [Related]
7. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein.
Neuhaus W; Stessl M; Strizsik E; Bennani-Baiti B; Wirth M; Toegel S; Modha M; Winkler J; Gabor F; Viernstein H; Noe CR
Neurosci Lett; 2010 Jan; 469(2):224-8. PubMed ID: 19963040
[TBL] [Abstract][Full Text] [Related]
9. P-Glycoprotein expression in human retinal pigment epithelium cell lines.
Constable PA; Lawrenson JG; Dolman DE; Arden GB; Abbott NJ
Exp Eye Res; 2006 Jul; 83(1):24-30. PubMed ID: 16530756
[TBL] [Abstract][Full Text] [Related]
10. Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model.
Pachot JI; Botham RP; Haegele KD; Hwang K
J Pharm Pharm Sci; 2003; 6(1):1-12. PubMed ID: 12753725
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells.
Ghetie MA; Ghetie V; Vitetta ES
Clin Cancer Res; 1999 Dec; 5(12):3920-7. PubMed ID: 10632321
[TBL] [Abstract][Full Text] [Related]
13. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
14. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
16. Expression of the human multidrug resistance gene mdr1 in leukemic cells and its application in studying P-glycoprotein antagonists.
Fu J; Chen Z; Cen J; Ruan C
Chin Med J (Engl); 2000 Mar; 113(3):228-31. PubMed ID: 11775252
[TBL] [Abstract][Full Text] [Related]
17. Drug-stimulated ATPase activity of a deletion mutant of the human multidrug-resistance protein (MDR1).
Welker E; Szabó K; Holló Z; Müller M; Sarkadi B; Váradi A
Biochem Biophys Res Commun; 1995 Nov; 216(2):602-9. PubMed ID: 7488154
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide does not interact with P-glycoprotein.
Zimmermann C; Gutmann H; Drewe J
Cancer Chemother Pharmacol; 2006 May; 57(5):599-606. PubMed ID: 16136308
[TBL] [Abstract][Full Text] [Related]
19. Cytometric study of intracellular P-gp expression and reversal of drug resistance.
Labroille G; Belloc F; Bilhou-Nabera C; Bonnefille S; Bascans E; Boisseau MR; Bernard P; Lacombe F
Cytometry; 1998 Jun; 32(2):86-94. PubMed ID: 9627221
[TBL] [Abstract][Full Text] [Related]
20. Interaction of imatinib mesilate with human P-glycoprotein.
Hamada A; Miyano H; Watanabe H; Saito H
J Pharmacol Exp Ther; 2003 Nov; 307(2):824-8. PubMed ID: 12975485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
